- Home
- BTAI vs INMB Comparison
BTAI vs INMB Comparison
Compare BTAI & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | INMB |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 40.1M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BTAI | INMB |
|---|---|---|
| Price | $1.62 | $1.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $26.67 | $4.30 |
| AVG Volume (30 Days) | ★ 494.6K | 324.9K |
| Earning Date | 03-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $752,000.00 | $50,000.00 |
| Revenue This Year | N/A | $264.29 |
| Revenue Next Year | $265.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.05 |
| 52 Week Low | $1.17 | $1.38 |
| 52 Week High | $8.08 | $11.64 |
Technical Indicators
Market Signals| Indicator | BTAI | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 49.78 |
| Support Level | $1.36 | $1.41 |
| Resistance Level | $1.72 | $1.74 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 45.10 | 48.72 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.